We are live on ! Find out more

2,075 hedge funds and large institutions have $145B invested in Pfizer in 2017 Q1 according to their latest regulatory filings, with 115 funds opening new positions, 858 increasing their positions, 909 reducing their positions, and 77 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more first-time investments, than exits

New positions opened: 115 | Existing positions closed: 77

5% more funds holding in top 10

Funds holding in top 10: 172180 (+8)

4% more capital invested

Capital invested by funds: $140B → $145B (+$5.17B)

1% more funds holding

Funds holding: 2,0592,075 (+16)

0.24% more ownership

Funds ownership: 70.78%71.02% (+0.24%)

6% less repeat investments, than reductions

Existing positions increased: 858 | Existing positions reduced: 909

26% less call options, than puts

Call options by funds: $1.5B | Put options by funds: $2.01B

Holders
2,075
Holders Change
+16
Holders Change %
+0.78%
% of All Funds
51.44%
Holding in Top 10
180
Holding in Top 10 Change
+8
Holding in Top 10 Change %
+4.65%
% of All Funds
4.46%
New
115
Increased
858
Reduced
909
Closed
77
Calls
$1.5B
Puts
$2.01B
Net Calls
-$513M
Net Calls Change
-$88.9M

PFE Hedge Fund Activity: Q1 2017 in Review

2,075 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q1 2017, worth a combined $145B — up 3.7% from $140B a quarter earlier.

Buyers outnumbered sellers: 115 funds opened new PFE positions and 77 closed out — a net gain of 38 holders — while 858 added to existing stakes and 909 trimmed.

The largest buyer was BlackRock, adding an estimated $14.3B. The largest seller was AllianceBernstein, cutting an estimated $368M.

  • 2,075 institutional investors held Pfizer (PFE) as of Q1 2017, up from 2,059 in Q4 2016.
  • Funds reported $145B of Pfizer stock for Q1 2017, up 3.7% quarter-over-quarter.
  • 115 funds opened new Pfizer positions in Q1 2017 and 77 closed out, a net change of +38 holders.
  • The largest Pfizer buyer in Q1 2017 was BlackRock, an estimated $14.3B added.
  • The largest Pfizer seller in Q1 2017 was AllianceBernstein, an estimated $368M sold.

Based on aggregated 13F filings for Q1 2017.